Loading provider…
Loading provider…
Hematology & Oncology Physician in MA
NPI: 1225015340HQ Phone
Get MD Frank's Phone Numberphone_androidMobile
Get MD Frank's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
MA State Medical License
2000 - 2026

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Rutgers New Jersey Medical School
njms.rutgers.edu
Medical School
Until 1996
Tufts Medical Center
Fellowship • Hematology and Medical Oncology
2002 - 2005
Residency • Pathology-Anatomic and Clinical
1996 - 1998
Boston University Medical Center
Residency • Internal Medicine
1998 - 2001
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
Authors: Carol Huff, Philip Wade, Kenneth Anderson, Nikhil Munshi, Jacob Laubach, Robert Schlossman
Publication Date: 2017-11-30
Docetaxel/Cyclophosphamide–Induced Ultraviolet Recall Dermatitis
Authors: Frank G. Basile, Sandra Creamer
Publication Date: 2011-12
Docetaxel/Cyclophosphamide-induced ultraviolet recall dermatitis.
Authors: Basile, Frank G, Creamer, Sandra
Journal: J Clin Oncol
Publication Date: 2011-10-24
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Exemestane, DRUG: Letrozole, DRUG: Anastrozole, DRUG: Tamoxifen Citrate, DRUG: Systemic Chemotherapy
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Genzyme, a Sanofi Company, Brigham and Women's Hospital, Millennium Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: bortezomib, DRUG: Dexamethasone, DRUG: Plerixafor
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: educational intervention, PROCEDURE: Physical therapy, OTHER: quality of life assessment